{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:52:08Z","timestamp":1760244728180,"version":"build-2065373602"},"reference-count":62,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cooperatio 11158207034-2: gastroenterology","award":["11158207034-2"],"award-info":[{"award-number":["11158207034-2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The global effort to eliminate HCV infection requires new approaches to accessing and testing the affected population in a setting with as low of a threshold as possible. The focus should be on socially marginalized people who inject drugs (PWIDs) and who are not willing or able to visit standard medical services. With this vision, we established an outreach service\u2014a testing point in an ambulance in the park in front of the Main Railway Station of the capital city of Prague\u2014to provide bloodborne disease testing and treatment. The service was available every week on Wednesday afternoon. Over the initial two years of our experience, 168 unique people were tested. Of them, 82 (49%) were diagnosed with chronic HCV infection and were eligible for treatment with antivirals. Of these, 24 (29%) initiated antiviral treatment over the study period, and 17 (71%) of these individuals achieved a documented sustained virological response. Offering medical services in PWIDs\u2019 neighborhoods helps overcome barriers and increase the chances that they will become patients and begin HCV treatment. The described outcomes appear promising for reaching the vision of linkage to the care of such a hard-to-reach population and can serve as a feasible model of care for further expansion.<\/jats:p>","DOI":"10.3390\/ijerph20010501","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T08:42:22Z","timestamp":1672216942000},"page":"501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pilot Outreach Program in Remedis\u2014The Promising Step toward HCV Elimination among People Who Inject Drugs"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3771-9663","authenticated-orcid":false,"given":"Laura","family":"Krekulov\u00e1","sequence":"first","affiliation":[{"name":"Remedis, s.r.o., Vladim\u00edrova 10, 140 00 Prague 4, Czech Republic"},{"name":"4th Department of Internal Medicine, First Faculty of Medicine, Charles University in Prague, Kate\u0159insk\u00e1 32, 128 00 Prague 2, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Damajka","sequence":"additional","affiliation":[{"name":"Remedis, s.r.o., Vladim\u00edrova 10, 140 00 Prague 4, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Krumphanslov\u00e1","sequence":"additional","affiliation":[{"name":"Remedis, s.r.o., Vladim\u00edrova 10, 140 00 Prague 4, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vratislav","family":"\u0158eh\u00e1k","sequence":"additional","affiliation":[{"name":"Remedis, s.r.o., Vladim\u00edrova 10, 140 00 Prague 4, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","article-title":"A systematic review of injecting-related injury and disease among people who inject drugs","volume":"171","author":"Larney","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","article-title":"Infectious Diseases and Injection Drug Use: Public Health Burden and Response","volume":"222","author":"Levitt","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","article-title":"Estimating the burden of disease attributable to injecting drug use as a risk factorfor HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013","volume":"16","author":"Degenhardt","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","unstructured":"World Health Organization (2016). Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection, World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., EMCDDA DRID group, Hatzakis, A., Prins, M., and Vickerman, P. (2014). Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103345"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"ref_7","unstructured":"World Health Organization (2017). Global Hepatitis Report 2017, World Health Organization."},{"key":"ref_8","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021: Towards Ending Viral Hepatitis, World Health Organization."},{"key":"ref_9","unstructured":"World Health Organization (2016). Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief, World Health Organization."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The he-patitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM)","volume":"10","author":"Martin","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs","volume":"28","author":"Hickman","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtbi.2010.12.041","article-title":"Mathematical modelling of hepatitis C treatment for injecting drug users","volume":"274","author":"Martin","year":"2011","journal-title":"J. Theor. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.drugpo.2015.05.005","article-title":"The promise of treatment as pre-vention for hepatitis C: Meeting the needs of people who inject drugs?","volume":"26","author":"Harris","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_16","unstructured":"Krekulova, L. (2021). Epidemie Virov\u00e9 Hepatitidy C v Rizikov\u00fdch Populac\u00edch: Diagnostika, L\u00e9\u010dba a Elimina\u010dn\u00ed Strategie, Stanislav Juha\u0148\u00e1k\u2014Triton."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of in-terferon \u03b12b plus ribavirin for 48 weeks or for 24 weeks versus interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepa-titis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon Alfa2b Alone or in Combination with Ribavirin as Initial Treatment or Chronic Hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"EASL (2022). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, P461\u2013P511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommenda-tions on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_22","first-page":"455","article-title":"Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection","volume":"69","author":"Husa","year":"2015","journal-title":"Gastroent. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study","volume":"2","author":"Razavi","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon Alfa2a plus Ribavirin for Chronic Hepatitis C Virus Infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginter-feron-\u03b12a and Ribavirin Combination Therapy in Chronic Hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_26","unstructured":"U.S. Food and Drug Administration (2011, January 27\u201328). Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting [Docket No. FDA\u20132011\u2013N\u20130002]. Proceedings of the Antiviral Drugs Advisory Committee Meeting, Silver Spring, MD, USA."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/14728214.2013.847089","article-title":"Emerging treatments for hepatitis C","volume":"18","author":"Flisiak","year":"2013","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepati-tis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"key":"ref_29","unstructured":"World Health Organization (WHO) (2019, July 09). Hepatitis C: Key Facts. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2012.08.002","article-title":"Thresholds in a low-thresh-old setting: An empirical study of barriers in a centre for people with drug problems and mental health disorders","volume":"24","author":"Skatvedt","year":"2013","journal-title":"Int. J. Drug Policy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/PPA.S49113","article-title":"Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review","volume":"7","author":"Mravcik","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C (17)30373-X","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","article-title":"Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists\u2014The practitioner experience","volume":"206","author":"Marshall","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Madden, A., Hopwood, M., Neale, J., and Treloar, C. (2018). Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207226"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.drugpo.2015.07.010","article-title":"Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs","volume":"26","author":"Larney","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109050","DOI":"10.1016\/j.drugalcdep.2021.109050","article-title":"Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system","volume":"228","author":"Gibbs","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jvh.13233","article-title":"Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study","volume":"27","author":"Bajis","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/dar.12883","article-title":"Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system","volume":"38","author":"Butler","year":"2019","journal-title":"Drug Alcohol Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drugpo.2019.02.012","article-title":"Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia","volume":"72","author":"Harney","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","article-title":"Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston","volume":"72","author":"Beiser","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103706","DOI":"10.1016\/j.drugpo.2022.103706","article-title":"Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study","volume":"105","author":"Valerio","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1353\/hpu.2017.0042","article-title":"Needs assessment of HCV-infected individuals experiencing homelessness and implications","volume":"28","author":"Beiser","year":"2017","journal-title":"J. Health Care Poor Underserved"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","article-title":"Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting","volume":"47","author":"Read","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102755","DOI":"10.1016\/j.drugpo.2020.102755","article-title":"Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada","volume":"80","author":"Broad","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"v17","DOI":"10.1093\/jac\/dkz452","article-title":"From peer-based to peer-led: Redefining the role of peers across the hepatitis C care pathway: HepCare Europe","volume":"74","author":"Surey","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.drugpo.2019.05.023","article-title":"Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review","volume":"72","author":"Socias","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jvh.12183","article-title":"Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study","volume":"21","author":"Treloar","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.puhe.2021.03.017","article-title":"Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia","volume":"195","author":"Stvilia","year":"2021","journal-title":"Public Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000092117","article-title":"Hepatitis C Virus Infection among Injecting Drug Users in the Czech Republic\u2014Prevalence and Associated Factors","volume":"12","author":"Zabransky","year":"2006","journal-title":"Eur. Addict. Res."},{"key":"ref_53","unstructured":"Mravcik, V., Chomynova, P., Grohmanova, K., Janikova, B., \u010cern\u00edkov\u00e1, T., Rous, Z., Le\u0161tinov\u00e1, T., Nechansk\u00e1, B., Cibulka, J., and Fidesova, H. (2019). V\u00fdro\u010dn\u00ed Zpr\u00e1va o Stavu ve V\u011bcech Drog v \u010cesk\u00e9 Republice v Roce 2018 (Annual Report on Drug Situation 2018\u2014Czech Republic), \u00da\u0159ad Vl\u00e1dy \u010cR."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future di-sease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infec-tion in a large community-based study of inner city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited Uptake of Hepatitis C Treatment Among Injection Drug Users","volume":"33","author":"Mehta","year":"2008","journal-title":"J. Commun. Health"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.drugpo.2015.07.007","article-title":"Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/jvh.13574","article-title":"Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis","volume":"28","author":"Yousafzai","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/S0618-8278(19)30671-1","article-title":"HCV care cascade of PWIDs reached within the Global Fund Needle and Syringe Program (NSP) in Georgia","volume":"70","author":"Stvilia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","article-title":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","volume":"70","author":"Iversen","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102837","DOI":"10.1016\/j.drugpo.2020.102837","article-title":"Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy","volume":"83","author":"Iversen","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: An updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/1\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:53:56Z","timestamp":1760147636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/1\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijerph20010501"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20010501","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}